As of March 1, 2024, an article processing charge (APC) of USD 400 + 20% VAT will be requested for newly submitted research, review, meta-analysis articles to the Anatolian Journal of Cardiology if they are accepted for publication.
Ximelagatran cannot be an alternative to standard warfarin therapy in chronic atrial fibrillation/ Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin? [Anatol J Cardiol]
Ximelagatran cannot be an alternative to standard warfarin therapy in chronic atrial fibrillation/ Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?
Yüksel Çavuşoğlu1Department of Cardiology and, Faculty of Medicine, Eskisehir Osmangazi University, Eskişehir-Turkey
Kronik atriyal fibrilasyonda ximelagatran warfarin’in alternatifi olamaz/Atriyal fibrilasyonda ximelagatran ile antitrombotik tedavi: Ximelagatran warfarin’e alternatif olabilir mi?
Yüksel Çavuşoğlu1Department of Cardiology and, Faculty of Medicine, Eskisehir Osmangazi University, Eskişehir-Turkey
Yüksel Çavuşoğlu. Ximelagatran cannot be an alternative to standard warfarin therapy in chronic atrial fibrillation/ Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?. Anatol J Cardiol. 2007; 7(2): 217-219 Manuscript Language: English